Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Patent
1990-06-18
1993-12-14
Nucker, Christine M.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
436811, 436813, 530328, 530327, 530326, 530325, 530324, 530350, 530380, C12Q 102, A61K 3702, A61K 3514, A61K 3704, C07K 500, C07K 700, C07K 1500, C07K 1700, C07K, C07K 1300
Patent
active
052701719
ABSTRACT:
A cancer recognition factor (SCM factor) useful in the performance of the structuredness of the cytoplasmic matrix (SCM) test has been isolated, purified to substantial homogeneity, and characterized, and methods for its use have been described. The factor is a peptide of at least 9 amino acid residues including a core sequence of 9 amino acid residues having an amphipathicity profile substantially equivalent to that of the sequence F-L-M-I-D-Q-N-T-K and produces at least a 10 percent decrease in the intracellular fluorescence polarization value of SCM-responding lymphocytes from donors afflicted with cancer. A synthetic SCM factor representing a consensus sequence of M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K is fully active. Antibodies specific for SCM factor are useful in immunoassays that can detect the factor, including detection in cancer cells grown in vitro. The SCM factor is useful for screening of blood samples and other body fluids or cell aspirates for the presence of malignancy in the donor. The multiple action spectrum of the SCM factor including cancer proliferation and invasion promotion, as well as inhibition of the host's immune defense mechanisms and synthesis of SCM factor by cancer cells, represents a novel target for cancer management. Methods for reducing in vivo activity of the SCM factor, such as dialysis or antibody neutralization, can also be useful in the management of cancer.
REFERENCES:
patent: 4001080 (1977-01-01), Goust et al.
patent: 4444744 (1984-04-01), Goldenberg
patent: 4645738 (1987-02-01), Knowles et al.
patent: 4657892 (1987-04-01), Brantl
Carrell et al. (1982) Nature 298:329-334.
Harris et al. (1987) Advances in Human Genetics Plenum Press, N.Y. pp. 1-62.
Stewart et al. (1979) Clin Immunol And Immunopathol 13:171-181.
Orjasaeter et al. (1979) B. J. Cancer 40:628-633.
L. Cercek, B. Cercek & C. I. V. Franklin, "Biophysical Differentiation Between Lymphocytes from Healthy Donors, Patients with Malignant Diseases and Other Disorders," Brit. J. Cancer 29, 345-52 (1974).
L. Cercek & B. Cercek, "Application of the Phenomenon of Changes in the Structuredness of Cytoplasmic Matrix (SCM) in the Diagnosis of Malignant Disorders: A Review," Europ. J. Cancer 13, 903-15 (1977).
L. Cercek & B. Cercek, "Changes in SCM-Responses of Lymphocytes in Mice After Implantation with Ehrlich Ascites Cells," Europ. J. Cancer 17, 167-71 (1981).
L. Cercek & B. Cercek, "Changes in the SCM Response Ratio (RR.sub.SCM) After Surgical Removal of Malignant Tissue," Brit. J. Cancer 31, 250-1 (1975).
L. Cercek & B. Cercek, "Apparent Tumour Specificity with the SCM Test," Brit. J. Cancer 31, 252-3 (1975).
S. Chaitchik, O. Asher, M. Deutsch & A. Weinreb, "Tumour Specificity of the SCM Test for Cancer Diagnosis," Eur. J. Cancer Clin. Oncol. 21, 1165-70 (1985).
J. A. V. Pritchard et al., "A Clinical Assessment of Fluorescence Polarisation Changes in Lymphocyte Stimulated by Phytohaemagglutinin (PHA) in Malignant and Benign Diseases," Eur. J. Cancer Clin. Oncol. 18, 651-9 (1982).
B. Cercek, "Letter to the Editor," Cancer 53, 17A-18A (1984).
L. Cercek & B. Cercek, "Letter to the Editor: Comments on `the SCM Test for Cancer, An Evaluation in Terms of Lymphocytes from Healthy Donors and Cancer Patients` by Mitchell, Wood, Pentycross and Bagshawe, Br. J. Cancer (1980) 41, 772," Br. J. Cancer 42, 947-9 (1980).
H. Orjasaeter, G. Jordfald & I. Svendsen, "Response of T-lymphocytes to Phytohaemagglutinin (PHA) and to Cancer-tissue-associated Antigens, Measured by the Intracellular Fluorescence Polarization Technique (SCM Test)," Br. J. Cancer 40, 628-33 (1979).
L. Cercek & B. Cercek, "Effects of Ascorbate Ions on Intracellular Fluorescein Emission Polarization Spectra in Cancer and Normal Proliferating Cells," Cancer Detection and Prevention 10, 1-20 (1987).
S. Stewart, K. I. Pritchard, J. W. Meakin & G. B. Price, "A Flow System Adaption of the SCM Test for Detection of Lymphocyte Response in Patients with Recurrent Breast Cancer," Clin. Immunol. & Immunopathol. 13, 171-81 (1979).
N. D. Schnuda, "Evaluation of Fluorescence Polarization of Human Blood Lymphocytes (SCM Test) in the Diagnosis of Cancer," Cancer 46, 1164-73 (1980).
K. Suzuki & Y. Sasaki, "Studies on Encephalitogenic Fragments of Myelin Protein. IV. Synthesis of Glycine Analogs of Tryptophan-containing Fragment," Chem. Pharm. Bull. 22, 2181-7 (1974).
A. A. Gershkovich, V. K. Kibirev, S. B. Serebryanyi, Y. T. Terletsckaya, E. P. Kozulina & Y. V. Belik, "A Study of the Properties of Synthetic Analogs of the Tryptophane-containing Fragment 113-121 of the Basic Protein of Myelin," Khim. Prirod. Soedinen. 4, 557-65 (1979).
C. M. Deber & M. E. M. Young, "Association of Carbon-13 Enriched Human Encephalitogenic Nonapeptide with a Membrane Surface," J. Biol. Chem. 254, 6341-5 (1979).
C. Blake & B. J. Gould, "Use of Enzymes in Immunoassay Techniques: A Review," Analyst 109, 533-47 (1984).
M. Oellerich, "Enzyme-Immunoassay: A Review," J. Clin. Chem. Clin. Biochem. 22, 895-904 (1984).
J. L. Marx, "How Cancer Cells Spread in the Body," Science 244, 147-8 (1989).
B. W. Hancock & R. C. Rees, "Interleukin-2 and Cancer Therapy," Cancer Cells 2, 29-32 (1990).
J. G. Kaplan & C. Bona, "Proteases as Mitogens: The Effect of Trypsin and Pronase on Mouse and Human Lymphocytes," Exp. Cell Res. 88, 388-94 (1974).
Y. Shai, T. K. Brunck & I. M. Chaiken, "Antisense Peptide Recognition of Sense Peptides: Sequence Simplification and Evaluation of Forces Underlying the Interaction," Biochemistry 28, 8804-11 (1989).
G. Fassina, M. Zamai, M. Brigham-Burke & I. M. Chaiken, "Recognition Properties of Antisense Peptides to Arg.sup.8 -Vasopressin/Bovine Neurophysin II. Biosynthetic Precursor Sequences," Biochemistry 28, 8811-18 (1989).
M. R. Potter & M. Moore, "Natural Cytotoxic Reactivity of Human Lymphocytes," Immunology 37, 187-94 (1979).
E. Cameron, A. Campbell & T. Jack, "The Orthomolecular Treatment of Cancer III. Reticulum Cell Sarcoma: Double Complete Regression Induced by High-dose Ascorbic Acid Therapy," Chem.-Biol. Interactions 11, 387-93 (1975).
N. Bishun, T. K. Basu, S. Metcalfe & D. C. Williams, "The Effect of Ascorbic Acid (Vitamin C) on Two Tumor Cell Lines in Culture," Oncology 35, 160-2 (1978).
S. Bram, P. Froussard, M. Guichard, C. Jasmin, Y. Augery, F. Sinoussi-Barre & W. Wray, "Vitamin C Preferential Toxicity for Malignant Melanoma Cells," Nature 284, 629-31 (1980).
J. L. Marx, "What T Cells See and How They See It," Science 242, 863-5 (1988).
W. Becker, "Determination of Antisera Titres Using the Single Radial Immunodiffusion Method," Immunochemistry 6, 539-46 (1969).
R. W. Carrell, J.-O. Jeppsson, C.-B. Laurell, S. O. Brennan, M. C. Owen, L. Vaughan & D. R. Boswell, "Structure and Variation of Human .alpha..sub.1 -Antitrypsin," Nature 298, 329-34 (1982).
M. Fagerhol & D. W. Cox, "The Pi Polymorphism; Genetic, Biochemical, and Clinical Aspects of Human .sub.1 -Antitrypsin," in Advances in Human Genetics (H. Harris and K. Hirschhorn, eds., Plenum Press, N.Y., 1981), vol. 11, pp. 1-62.
W. Troll, M. S. Meyn & T. G. Rossman, "Mechanisms of Protease Action in Carcinogenesis," in Carcinogenesis--A Comprehensive Survey, vol. II: Mechanisms of Tumor Promotion and Cocarcinogenesis (T. J. Slaga, A. Sivak & R. K. Boutwell, eds., Raven Press, N.Y., 1978), pp. 301-312.
T. G. Rossman & W. Troll, "Protease Inhibitors in Carcinogenesis: Possible Sites of Action," in Carcinogenesis, vol. V: Modifiers of Chemical Carcinogenesis (T. J. Slaga, ed., Raven Press, N.Y. 1980) pp. 127-148.
G. J. Cianciolo, "Anti-inflammatory Effects of Neoplasia," in Inflammation: Basic Principles and Clinical Correlates (J. I. Gallin, I. M. Goldstein & R. Snyderman, eds., Raven Press, N.Y., 1988) Ch. 48, pp. 861-874.
E. Reich, "Tumor-associated Fibrinolysis," Fed. Proc. 32, 2174-5 (1973).
H. B. Bosmann, "Release of Specific Protease During Mitotic Cycle of L5178Y Murine Leukaemic Cells by Sublethal Autolysis," Nature 249, 144-5 (1974).
I. Hayashi & B. I. Carr, "DNA Synthesis in Rat Hepatocytes: Inhibition by a Platelet Factor and Stimulation by an Endogenous Fact
Cercek Boris
Cercek Lea
Nucker Christine M.
Preston D. R.
LandOfFree
Cancer-associated SCM-recognition factor, preparation and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer-associated SCM-recognition factor, preparation and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer-associated SCM-recognition factor, preparation and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1704391